Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b randomized double-blind dose-ranging study of clazakizumab in TNF inhibitor inadequate responder rheumatoid arthritis
jRCT2080222447Phase 2
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of clazakizumab in rheumatoid arthritis (RA) (3 arms), sponsored by Bristol Myers Squibb.
02
Drugs
clazakizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on jRCT2080222447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222447.